|Day Low/High||231.34 / 235.38|
|52 Wk Low/High||129.21 / 275.87|
I am flat LLY for now. Let's see how the shares behave around the technicals. Then we'll make an equity decision.
Just how many markets are there? We used to say 'the market' was up or down by so many points. No more.
Right now, the market is furiously trying to price in a Blue Wave, and the health care sector is getting clobbered. But here's how I think things play out.
The 'work from home' or 'economic lockdown' trade is close to being back on.
This is a major earnings week, electoral risk is real, the virus is already slowing velocity, and the cavalry (fiscal policy) is not coming. Sometimes, circling the wagons is not the worst idea.
Portfolio managers are starting to see a very strong 2021 for markets and the economy regardless of electoral results.
Markets have certainly recovered nicely off of the lows of late September. Now, here in mid-October, it feels like it did that cold night back in 1980-something. The wolves are visible and noisy.
Covid itself, and therapeutics or vaccines associated with taking on the SARS-CoV-2 coronavirus, is under a public microscope.
Market participants ignore negative news and continue to pursue individual stocks into earnings season.
Given the news of the day, you'd think we would have had a violent pullback -- instead here's what we got.
Some patterns reveal themselves easily, and you can spot them ahead of the computer programs. Here are examples of them, and how to act.
Let's talk about what's happening right now to get this thing under control and what it will look like not that long from now.
What stocks do from here will, beyond electoral risk and potential stimulus, rely upon fourth quarter guidance.
Invest either because of their profitable portfolio, their impressive pipeline, or their technical set-up.
As psychedelic medicines begin to become decriminalized, psilocybin seems to be leading the way in this category.
RedHill Biopharma has adopted 'Veeva Vault CDMS', Veeva's modern cloud platform.
Successful tests of a rising 200-day moving average line can be great entry points for longs.
Electoral risk remains the monster under the bed, and it only grows as our legislators intentionally choose the blame game over honest cooperation.
6 favorite stocks and ETFs in the biotech and pharmaceutical sector, including a diversified basket of Covid-19 vaccine names.
Do these shares get back to the 2020 highs that were reached back in January?
The buyers have decided that the researchers and doctors are going to beat the virus, so you better get on board or miss the move.
Our fate is in the hands of a few dozen companies with a dizzying array of clinical trials, and whoever gets there first is gonna make a fortune.
Let's take a close look at Gilead Sciences, Regeneron and Eli Lilly.
These pharmaceutical favorites continue to make progress on a number of fronts including a Covid-19 vaccine.
Potential for a new blockbuster breast cancer treatment is eyed as possible game changer, so let's see the charts and indicators for a new target.
So what's the narrative? Simple: the recession is ending, it turned out to be a V recession and recovery after all.
The question is whether you want to buy before the breakout or after the breakout?
The bullish reversal pattern is appearing not just in single names, but also in whole sectors.
Here are my thoughts on the quarter and trading the stock.
Watching first-time jobless claims and trading volume, plus some thoughts on defense names like Raytheon and Lockheed Martin, and tech names like Lam Research.